Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626828 | 0.87 | CYP3A4 (0.50) | CYP17A1CYP3A4HRH4HRH3CYP19A1 | |
| Trifluoroacetic Acid SCHEMBL2074049 | 0.72 | IDO1 (0.70) | CYP3A4HRH4HRH3SMN1; SMN2 | |
| SCHEMBL28700033 | 0.71 | CYP3A4 (0.40) | CYP17A1CYP3A4HRH4HRH3CYP19A1 | |
| 4-Imidazolecarboxylic Acid SCHEMBL17143063 | 0.69 | HRH3 (0.53) | CYP3A4HRH4HRH3NPC1TP53 | |
| SCHEMBL5681197 | 0.67 | CYP3A4 (0.47) | CYP17A1CYP3A4HRH4HRH3CYP19A1 | |
| Trifluoroacetic Acid SCHEMBL28429332 | 0.67 | CYP1A2 (0.50) | RAB9A | |
| Trifluoroacetic Acid SCHEMBL3635857 | 0.66 | HRH3 (0.54) | CYP3A4HRH4HRH3NPC1TP53 | |
| Trifluoroacetic Acid SCHEMBL27504505 | 0.65 | MAPT (0.44) | CYP3A4 | |
| SCHEMBL5784709 | 0.65 | CYP17A1 (0.41) | CYP17A1CYP3A4HRH4CYP19A1 | |
| Trifluoroacetic Acid SCHEMBL28162943 | 0.65 | HRH4 (0.49) | CYP3A4HRH4HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | claimed |
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | CYP17A1 435/4885CYP3A4 38/4885HRH4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.